NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange [Yahoo! Finance]
NervGen Pharma Corp. - Common stock (NGEN)
Company Research
Source: Yahoo! Finance
NervGen Pharma Corp. The Company's common shares will continue to trade on Nasdaq under the symbol “NGEN” No action is required; all shareholders, including Canadian shareholders, will continue to maintain full trading access on Nasdaq VANCOUVER, British Columbia, March 12, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced that the Company has elected to voluntarily delist its common shares from TSX Venture Exchange (“TSXV”), effective at the close of markets on March 16, 2026. This strategic decision reflects NervGen's continued maturity and aligns with the Company's evolution as it enters late-stage development for NVG-291. Following a comprehensive evaluation, the Company determined that maintaining a dual listing on TSXV does n
Show less
Read more
Impact Snapshot
Event Time:
NGEN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NGEN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NGEN alerts
High impacting NervGen Pharma Corp. - Common stock news events
Weekly update
A roundup of the hottest topics
NGEN
News
- NervGen Pharma: I See Promise, But The Clock Is Ticking (Rating Downgrade) [Seeking Alpha]Seeking Alpha
- NervGen Pharma Announces Voluntary Delisting from TSX Venture ExchangeGlobeNewswire
- NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical AffairsGlobeNewswire
- NervGen Pharma to Participate at Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
- NervGen Pharma to Participate at Upcoming Investor ConferencesGlobeNewswire
NGEN
Sec Filings
- 3/13/26 - Form 6-K
- 2/13/26 - Form 6-K
- 2/10/26 - Form 6-K
- NGEN's page on the SEC website